natgillin/translations-raw huggingface dataset:
Doctors should check the patient's liver before starting treatment with Tasmar and then regularly during treatment. 
Zdravniki morajo pregledati bolnikova jetra pred začetkom zdravljenja z zdravilom Tasmar ter nato redno med samim zdravljenjem.
For the full list of restrictions see the package leaflet. 
Za celoten seznam omejitev glejte navodilo za uporabo.
Other information about Tasmar 
Druge informacije o zdravilu Tasmar
A risk management plan has been developed to ensure that Tasmar is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Tasmar je bil pripravljen načrt obvladovanja tveganj.
• severe dyskinesia. 
• s hudo diskinezijo.
Tasmar is only used when patients do not respond, or cannot take other medicines of the same type. 
Zdravilo Tasmar se uporablja samo, kadar se bolnik ne odziva na druga zdravila iste vrste ali jih ne more jemati.
The study compared continuing to take entacapone with switching to Tasmar. 
V študiji so primerjali nadaljevanje jemanja entakapona s prehodom na zdravilo Tasmar.
Tasmar treatment should only be prescribed and supervised by a doctor who has experience in the management of advanced Parkinson's disease. 
Zdravljenje z zdravilom Tasmar mora predpisati in nadzorovati samo zdravnik z izkušnjami z zdravljenjem napredovale Parkinsonove bolezni.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tasmar. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Tasmar shown during the studies? 
Kakšne koristi je zdravilo Tasmar izkazalo med študijami?
For more information about treatment with Tasmar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Tasmar preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The Committee recommended that Tasmar be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Tasmar odobri dovoljenje za promet.
When patients add Tasmar to their existing anti Parkinson's disease medication, they need to be made aware that they may experience some of the side effects of levodopa, although these can often be reduced by lowering the dose of levodopa. 
Ko bolniki dodajajo zdravilo Tasmar svojemu obstoječemu zdravljenju Parkinsonove bolezni, morajo biti opozorjeni, da bodo morda občutili nekatere neželene učinke levodope, ki pa jih je pogosto možno ublažiti z zmanjšanjem njenega odmerka.
Tasmar must not be used in patients with: 
Zdravila Tasmar ne smejo uporabljati bolniki:
The main measure of effectiveness was the number of patients with an increase in ‘on' time of one hour or more, during the three weeks following the switch. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je vključitveno obdobje podaljšalo za eno uro ali več v treh tednih, ki so sledili prehodu na drugo zdravilo.
Tasmar is a medicine that contains the active substance tolcapone. 
Tasmar je zdravilo, ki vsebuje zdravilno učinkovino tolkapon.
The most common side effects with Tasmar (seen in more than 1 patient in 10) are nausea (feeling sick), loss of appetite, diarrhoea, dyskinesia (uncontrollable movements), dystonia (muscle spasms), headache, dizziness, sleep disorders, excessive dreaming, somnolence (sleepiness), confusion, hallucination (seeing things that are not there) and orthostatic complaints (dizziness on standing). 
Najpogostejši neželeni učinki zdravila Tasmar (opaženi pri več kot 1 bolniku od 10) so navzeja (slabost), izguba teka, driska, diskinezija (nekontrolirani gibi), distonija (krči v mišicah), glavobol, omotica, motnje spanja, pretirano sanjanje, zaspanost, zmedenost, halucinacije (prividi) in ortostatične motnje (vrtoglavica v stoječem položaju).
Tasmar must also not be used in patients who are being treated with medicines known as nonselective monoamine oxidase (MAO) inhibitors. 
Zdravila Tasmar prav tako ne smejo jemati bolniki, ki jemljejo zdravila, znana kot neselektivni zaviralci monoaminooksidaze (MAO).
Tasmar is used to treat patients with Parkinson's disease. 
Zdravilo Tasmar se uporablja za zdravljenje bolnikov s Parkinsonovo boleznijo.
This helps to improve the signs and symptoms of Parkinson's disease, such as stiffness and slowness of movement. 
To pomaga pri izboljšanju znakov in simptomov Parkinsonove bolezni, kot sta otrplost mišic in upočasnjeno izvajanje gibov.
What is the risk associated with Tasmar? 
Kakšna tveganja so povezana z zdravilom Tasmar?
Tasmar can cause liver injury, which can be fatal in rare cases. 
Zdravilo Tasmar lahko povzroči okvaro jeter, ki je v redkih primerih lahko usodna.
The first dose of the day of Tasmar should be taken together with the first daily dose of the levodopa preparation, and subsequent doses of Tasmar should be given approximately 6 and 12 hours later. 
Priporočeni odmerek je 100 mg trikrat na dan. Prvi dnevni odmerek zdravila Tasmar je treba vzeti skupaj s prvim dnevnim odmerkom pripravka z levodopo, nadaljnje odmerke zdravila Tasmar pa je treba dati približno 6 in 12 ur kasneje.
The active substance in Tasmar, tolcapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination. 
Zdravilna učinkovina v zdravilu Tasmar, tolkapon, deluje tako, da ponovno vzpostavi ravni dopamina v delu možganov, ki nadzoruje gibanje in njihovo usklajenost.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tasmar, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
In patients with Parkinson's disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases. 
Pri bolnikih s Parkinsonovo boleznijo začnejo celice v možganih, ki proizvajajo živčni prenašalec dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
• a history of neuroleptic malignant syndrome (a dangerous nervous disorder usually caused by antipsychotic medicines), rhabdomyolysis (breakdown of muscle fibres) or hyperthermia (heat stroke); 
• ki so imeli kdaj v preteklosti nevroleptični maligni sindrom (nevarne živčne reakcije, ki jih običajno povzročijo antipsihotična zdravila), rabdomiolizo (razgradnjo mišičnega tkiva) ali hipertemijo (vročinsko kap);
It only works when it is taken with levodopa, a copy of the neurotransmitter dopamine that can be taken by mouth. 
Deluje samo pri uporabi skupaj z levodopo, kopijo živčnega prenašalca dopamina, ki se lahko jemlje peroralno.
Tasmar is used together with other standard treatments for Parkinson's disease (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patients have ‘fluctuations' towards the end of the period between two doses of their standard combination. 
Zdravilo Tasmar se uporablja skupaj z drugimi standardnimi zdravljenji Parkinsonove bolezni (bodisi s kombinacijo levodope in benserazida bodisi levodope in karbidope) pri bolnikih z „nihanji“ proti koncu obdobja med dvema odmerkoma običajne kombinacije zdravil.
Tasmar is always given with levodopa and benserazide or with levodopa and carbidopa. 
Zdravilo Tasmar se vedno daje z levodopo in benserazidom ali z levodopo in karbidopo.
• phaeochromocytoma (a tumour of the adrenal gland); 
• s feokromocitomom (tumorjem nadledvične žleze);
Parkinson's disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness. 
Parkinsonova bolezen je napredujoča okvara možganov, ki povzroča tresenje, upočasnjeno izvajanje gibov in otrplost mišic.
All of the studies compared Tasmar with placebo (a dummy treatment) when they were added to the patient's existing medication (levodopa and either carbidopa or benserazide). 
V vseh študijah so zdravilo Tasmar primerjali s placebom (zdravilom brez zdravilne učinkovine), ki so ju dodajali zdravilom, ki jih je bolnik že jemal (levodopi in bodisi karbidopi ali benserazidu).
For the full list of all side effects reported with Tasmar, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tasmar, glejte navodilo za uporabo.
Why has Tasmar been approved? 
Zakaj je bilo zdravilo Tasmar odobreno?
These patients were already receiving a combination of levodopa and entacapone (another medicine that blocks COMT). 
Ti bolniki so že prejemali kombinacijo levodope in entakapona (drugega zdravila, ki zavira katehol-O-metiltransferazo).
Fluctuations are linked with a reduction in the effects of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and immobile. 
Nihanja so povezana z zmanjšanim učinkom levodope, ko bolnik doživlja nenadne preskoke med stanjem, ko se lahko giblje (vključitveno obdobje), in med stanjem, ko se ne more premikati (prekinitveno obdobje).
The CHMP decided that Tasmar's benefits are greater than its risks in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who failed to respond to or are intolerant of other COMT inhibitors. 
CHMP je sklenil, da so koristi zdravila Tasmar v kombinaciji z levodopo/benserazidom ali levodopo/karbidopo za uporabo pri bolnikih z idiopatsko Parkinsonovo boleznijo, odzivno na levodopo, in motoričnimi nihanji, ki se niso odzvali na druge zaviralce encima COMT ali pa jih ne prenašajo, večje od z njim povezanih tveganj.
Treatment should be stopped in patients who develop liver problems. 
Pri bolnikih, pri katerih se pojavijo težave z jetri, je treba zdravljenje prekiniti.
The main measure of effectiveness was how long the patients spent in the ‘off' or in the ‘on' state. 
Glavno merilo učinkovitosti je bil čas, ki ga je bolnik preživel v vključitvenem oziroma prekinitvenem obdobju.
Tolcapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catecholO-methyl transferase (COMT). 
Tolkapon zavira encim, imenovan katehol-O-metiltransferaza (COMT), ki sodeluje pri razgradnji levodope v telesu.
What is Tasmar? 
Kaj je zdravilo Tasmar?
What is Tasmar used for? 
Za kaj se zdravilo Tasmar uporablja?
There was a reduction of about 20 to 30% in ‘off' time in patients taking Tasmar. 
Pri bolnikih, ki so jemali zdravilo Tasmar, se je prekinitveno obdobje skrajšalo za 20 do 30 %.
How has Tasmar been studied? 
Kako je bilo zdravilo Tasmar raziskano?
How does Tasmar work? 
Kako zdravilo Tasmar deluje?
How is Tasmar used? 
Kako se zdravilo Tasmar uporablja?
ANNEX 
Page 2/2
Physicians and patients should be made aware that there is an ad hoc advisory service available to provide information on leflunomide plasma level laboratory testing 
Zdravnike in bolnike je potrebno obvestiti, da je na razpolago za ta namen posvetovalna služba za posredovanje informacij o laboratorijskem testiranju plazemskih vrednosti leflunomida.
The Member States shall ensure that the Marketing Authorisation Holder (MAH) will provide physicians who are expected to prescribe/use Leflunomide medac with a physician educational pack containing the following: 
Država članica mora zagotoviti, da bo imetnik dovoljenja za promet z zdravilom poskrbel, da bodo vsi zdravniki, za katere se pričakuje, da bodo zdravilo Leflunomide medac predpisovali ali uporabljali, dobili izobraževalno gradivo, ki vsebuje:
• That there is a risk of teratogenicity and so pregnancy must be avoided until leflunomide plasma levels are at an appropriate level. 
• Da obstaja tveganje za teratogenost, zato se je potrebno izogniti nosečnosti dokler niso doseženi primerne plazemske vrednosti leflunomida.
• The Summary of Product Characteristics • Physician Leaflet 
• Povzetek glavnih značilnosti zdravila • Navodilo za zdravnika
• The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate) 
• O ugotovljenem tveganju za sinergistično hepato ali hemato toksičnost v povezavi s kombinirano terapijo z drugimi imunomodulirajočimi protirevmatičnimi zdravili (diseasemodifying antirheumatic drug (DMARD) zdravili (na primer metotreksat).
These effects will usually resolve without treatment. 
Ti učinki bodo navadno izginili brez zdravljenja.
In case of accidental exposure of cats: 
V primeru nenamerne izpostavljenosti mačk:
Recovery occurs normally within 24-36 hours after treatment. 
Do okrevanja pride običajno v 24-36 urah po zdravljenju.
Date of latest renewal: 14/12/2016. 
Datum zadnjega podaljšanja: 14/12/2016
• on the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children; 
• na dan zdravljenja se otroci ne smejo dotikati zdravljene živali in živali ne smejo spati z lastniki, posebno ne z otroki,
A proper treatment of the pet´s environment by additional chemical or physical measures is recommended. 
Priporoča se ustrezna obdelava okolja za hišne ljubljenčke z dodatnimi kemičnimi ali fizikalnimi ukrepi.
10 DATE OF REVISION OF THE TEXT 
DATUM REVIZIJE BESEDILA
See section 6.6 
Glejte poglavje 6.6.
In case of frequent shampooing, the duration of activity may be reduced. 
V primeru pogostega šamponiranja se trajanje učinkovanja lahko zmanjša.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMA) http://www.ema.europa.eu/.
Used pipettes should be disposed of immediately. 
Uporabljene merilne kapalke je treba takoj zavreči.
To avoid adverse reactions: 
Da bi se izognili neželenim učinkom:
These signs are usually transient and generally resolve within 24 - 48 hours. 
Ti znaki so navadno prehodni in na splošno izginejo v 24 do 48 urah.
This is normal and will generally resolve within a couple of days after administration. 
To je normalno in se navadno razreši v nekaj dneh po dajanju.
These changes do not affect the safety or efficacy of the veterinary product. 
Te spremembe ne vplivajo na varnost ali učinkovitost zdravila.
Absorption through the skin also occurs, but this systemic absorption is partial and not relevant for the clinical efficacy. 
Raztopina se absorbira tudi skozi kožo, toda ta sistemska absorbcija je le delna in ni pomembna za klinično učinkovitost.
The expiry date refers to the last day of that month. 
Rok uporabnosti zdravila se nanaša na zadnji dan v navedenem mesecu.
The appropriate combination of pipettes should be used 
Uporabiti je treba primerno kombinacijo merilnih kapalk.
0.5 Minimum of 15 Minimum of 48 
0,5 najmanj 15 najmanj 48
Do not eat, drink or smoke while handling the veterinary medicinal product. 
Ne jejte, pijte ali kadite, ko delate z zdravilom za uporabo v veterinarski medicini.
If this occurs, rinse slowly and gently with water. 
Če se to zgodi, spirajte počasi in narahlo z vodo.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Weight of dog (kg) 
Teža psa (kg)
This results in a rapid cessation of feeding within 0 to 4 hours after treatment followed by cessation of egg laying (oviposition), paralysis and death occurring within 4 to 48 hours. 
To povzroči hitro prenehanje hranjenja v 0 do 4 urah po zdravljenju, čemur sledi prenehanje odlaganja jajčec, paraliza in smrt nastopita v 4 do 48 urah.
ATCvet code: QP53AC54. 
Oznaka ATC vet: QP53AC54
Keep away from heat, sparks, open flame or other sources of ignition. 
Hranite ga stran od vročine, isker, odprtega ognja ali drugih virov vžiga.
EU/2/11/137/001-015 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/2/11/137/001-015
Step 1: Hold the pipette in an upright position away from your face. 
Prvi korak: Merilno kapalko držite v pokončnem položaju stran od obraza.
Step 2: The dog should be standing for easy application. 
Drugi korak: Pes naj stoji, da je nanašanje lažje.
• wear protective gloves when handling or applying the product; 
• nosite zaščitne rokavice, ko rokujete z zdravilom ali ga nanašate,
4.7 Use during pregnancy, lactation or lay 
4.7 Uporaba v obdobju brejosti, laktacije in nesnosti
A dry white residue may also be observed. 
Včasih lahko opazite tudi suh bel ostanek.
Activyl Tick Plus should not enter water courses as this may be dangerous for fish and other aquatic organisms. 
Activyl Tick plus ne sme priti v vodotoke, ker je to lahko nevarno za ribe in druge vodne organizme.
Open one sachet and remove the pipette. 
Odprite eno vrečko in izvlecite merilno kapalko.
Special warnings for each target species: 
Posebna opozorila za vsako ciljno živalsko vrsto:
This product is highly flammable. 
To zdravilo je zelo vnetljivo.
However, dogs should not be allowed to swim or be shampooed within 48 hours after treatment. 
Vendar pa psom ne smete dovoliti plavanja ali jih šamponirati 48 ur po zdravljenju.
PROHIBITION OF SALE, SUPPLY AND/OR USE 
PREPOVED PRODAJE, OSKRBE IN/ALI UPORABE Ni smiselno.
Do not administer orally or via any other route. 
Zdravila ne uporabljajte peroralno ali po drugi poti uporabe.
For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder. 
Za vse nadaljnje informacije o tem zdravilu se obrnite na krajevno predstavništvo imetnika dovoljenja za promet z zdravilom.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION 
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE
No adverse reactions were observed in dogs aged 8 weeks and older, treated 8 times at 4 week intervals or 6 times at 2 week intervals, with 5 times the recommended dose. 
Nobenih neželenih učinkov niso opazili pri psih, starih 8 tednov ali več, ki so jim dali 5-kratni priporočeni odmerek 8-krat v 4-tedenskih razmakih ali 5-kratni priporočeni odmerek 6-krat v 2tedenskih razmakih.
Ticks already attached on the dog may not be killed within two days after treatment and may remain attached and visible. 
Klopi, ki se že držijo na psu, morda ne bodo pomrli v dveh urah po zdravljenju in ostanejo na koži in so vidni.
Disposal: read package leaflet. 
Odstranjevanje: Preberite navodilo za uporabo.
The pipette consists of a blister film (polypropylene/cyclic-olefin- copolymer/polypropylene) and a foil lidstock (aluminium/polypropylene co-extruded) sealed into aluminium child-resistant sachet. 
Merilna kapalka je sestavljena iz pretisnega filma (polipropilen/ciklični olefin kopolimer/polipropilen) in pokrovčka iz folije (stisnjen aluminij/polipropilen) ter zavarjena v aluminijasto za otroke varno vrečko.
It enters the insect primarily through ingestion but is also absorbed, to a lesser degree, through the insect cuticle. 
V insekta pride predvsem z zaužitjem, se pa v manjši stopnji tudi absorbira skozi njegovo povrhnjico.
Manufacturer responsible for batch release: Intervet Productions SA Rue de Lyons 
Proizvajalec, odgovoren za sproščanje serij: Intervet Productions SA Rue de Lyons
Indoxacarb is an ectoparasiticide belonging to the oxadiazine chemical family. 
Indoksakarb je ektoparaziticid, ki spada v kemijsko skupino oksadiazinov.
If ticks of these species are present when the product is applied, all the ticks may not be killed within the first 48 hours but they may be killed within a week. 
Če so klopi teh vrst prisotni, ko nanašate zdravilo, morda vsi ne bodo uničeni v prvih 48 urah ampak v enem tednu.
Special precautions for use in animals: The product should not be used in dogs younger than 8 weeks or dogs weighing less than 1.2 kg. 
Posebni previdnostni ukrepi za uporabo pri živalih: Zdravilo se ne sme uporabljati pri psih, mlajših od 8 tednov in pri psih, ki tehtajo manj kot 1,2 kg.
Developing stages of fleas in the dog's immediate surroundings are killed following contact with the treated dogs. 
Razvojne stopnje bolh v neposredni okolici psa se po stiku z zdravljenimi psi uničijo.
• as the veterinary medicinal product may cause moderate eye irritation, avoid contact with eyes. 
Ker zdravilo za uporabo v veterinarski medicini lahko povzroči zmerno draženje oči, se izogibajte stiku z očmi.
Pyrethroids are so-called “open channel blockers” affecting the sodium channel by slowing both the activation and the inactivation properties, thus leading to hyper-excitability and death of the parasite. 
Piretroidi so tako imenovani “zaviralci odprtih kanalov”, ki delujejo na natrijev kanal tako, da upočasnijo aktivacijske in neaktivacijske lastnosti in tako vodijo do prevelike vzdražljivosti in smrti parazita.
Intervet Productions SA Rue de Lyons 27460 Igoville France 
Intervet Productions S.A. Rue de Lyons 27460 Igoville Francija
1.2 - 5 Very small dogs 
1,2 - 5 zelo majhni psi
CLINICAL PARTICULARS 4.1 Target species 
KLINIČNI PODATKI 4.1 Ciljne živalske vrste
DANGER - Do not use in cats as adverse reactions and even death can occur (see also section Special precautions for use in animals). 
NEVARNOST - Ne uporabite pri mačkah zaradi možnosti pojava neželenih učinkov in celo smrti (glejte poglavje Posebni previdnostni ukrepi za uporabo pri živalih).
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs 
A. PROIZVAJALEC (PROIZVAJALCI) ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
The veterinary medicinal product remains effective when treated dogs are exposed to sunlight or immersed in water (e.g. swimming, bathing). 
Zdravilo za uporabo v veterinarski medicini še naprej učinkuje, če so zdravljeni psi izpostavljeni soncu ali se zmočijo v vodi (npr. plavanje, kopanje).
The product should not be used in dogs younger than 8 weeks or dogs weighing less than 1.2 kg. 
Zdravilo se ne sme uporabljati pri psih, mlajših od 8 tednov in pri psih, ki tehtajo manj kot 1,2 kg.
The bioactivated metabolite acts as a voltage-dependent sodium channel antagonist in insects, by blocking the sodium channels that regulate the flow of sodium ions in the insect's nervous system. 
Bioaktivirani metabolit deluje kot od napetosti odvisni antagonist natrijevih kanalov pri insektih z zaviranjem natrijevih kanalov, ki uravnavajo tok natrijevih ionov v živčnem sistemu insekta.
Part the hair until the skin is visible and place the pipette tip against the skin between the shoulder blades. 
Razmaknite dlako, da se vidi koža in nastavite merilno kapalko na kožo med ramenske lopatice.
Signs of poisoning are severe tremors, muscle cramp and ataxia. 
Znaki zastrupitve so hud tremor, mišični krči in ataksija.
Do not use in cats as adverse reactions and even death can occur (see also section 4.5 Special precautions for use in animals). 
Ne uporabljajte za mačke zaradi možnosti pojava neželenih učinkov in celo smrti (glejte poglavje 4.5 Posebni previdnostni ukrepi).
Do not use in cats. 
Ne uporabite pri mačkah.
In case of accidental dermal exposure, wash the cat with shampoo or soap, and seek veterinary advice rapidly. 
V slučaju nenamernega dermalnega izpostavljanja, operite mačko s šamponom ali milom in hitro obiščite veterinarja.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Active substances: 
NAVEDBA UČINKOVIN(E) IN DRUG(E)IH SESTAVIN Učinkovina: